Prospective study dose intensified SBRT vertebral oligomets · Excellent local control sciencedirect.com/science/articl…

Happy to share our report on an NLP + targeted human approach deployed over 1.5 years across 8.6M clinical notes to detect and refer inflammatory breast cancer cases to a specialized IBC clinic Wendy Woodward MDPhD academic.oup.com/jncics/advance…

Led by Drs. Zakeri & Nancy Lee, we report early Memorial Sloan Kettering Radiation Oncology exp w/ 40 Gy ENI + CCRT for larynx, HPX, p16- OPX + CUP, 97.3% platinum, no uninvolved 1B+5 ☑️73 pts, f/u 23 months ✅no solitary elective failures, all LRF include 70 Gy failures ✅good QoL 👉 shorturl.at/CKA6W

‼️ PACE-C RCT Prostate cancer -> 60 Gy/20 fx vs 36.25 Gy/5 fx Grade 2+ CTCAE GI toxicity: 10% vs 17% favoring 20 fx, p=0.0011 Grade 2+ CTCAE GU toxicity: 28% vs 34% favoring 20 fx, p=0.050 Why do a more toxic regimen with 5 fx? 👎 👎 👎

💥New Paradigm for the pathophysiology of Osteoarthritis (OA) The understanding of OA pathophysiology has undergone a paradigm shift, moving from a mechanical “wear and tear” model to one emphasizing synovial inflammation and immune-mediated joint degeneration. Here’s how

While I'm here, I'll just point out that RCTs of SABR don't show that radiation leads to more metastases...if anything the relationship is going the other way. Here's the data from Dan Gomez's oligomets RCT...

SURF-RCT (Randomised) Ph III + COHORT (Nonrandomised) SURGERY Vs RFA for HCC <3 cm & <3 nodules 1094 registered (2009-2015) 302 agreed for Randomisation, 753 denied 5y OS=74.6% (Sx) Vs 70.4%(RFA) HR=0.96,P=0.96 5yRFS= 42.9% (Sx) Vs 42.7%(RFA) HR=0.90,p=0.84 Sx=RFA for small HCC

T1NoMo.TNBC Retrospective SEER (2010-2020) Adj=8146; Neoadj=1263 Recent ↑ in NAC (5 to 30%) No difference in BCSS or OS for patients with T1b/T1cN0 T1aN0 TNBC had worse BCSS & OS when treated with NACT Vs Adj T1aN0 had lower pCR rate than T1cN0 (18% vs. 47%) pCR=Better outcomes

Great paper European Urology confirming safety of #activesurveillance for #prostatecancer out to 25 years in the Göteborg-1 trial. dx.doi.org/10.1016/j.euru…

🚨ACCORD Trial🚨 Resected Extrahepatic CCA or Gallbladder CA 🔍Randomized Adjuvant CRT + Camrelizumab vs Observation 🔥Whopping improvement in OS and RFS with CRT + ICI with persistent separate at tail of the curve!!! tinyurl.com/64yc3uum JAMA Oncology

Chad Tang, MD & I happy to report: ph2 basket EXTEND-OP trial has enrolled and randomized 150 patients in the last year since opening: - 7 histology-specific baskets - Oligoprogressive dz randomized to: ☢ Local Tx + continued same-line systemic, versus 💊Switching systemic Tx

Great work out in European Urology Oncology led by Jesus E. Juarez C. outstanding PGY-5 UCLA Jonsson Comprehensive Cancer Center . Pooled analysis of two trials of androgen annihilation (ADT+AAP+apa) and RP/RT plus MDT in de novo mHSPC or oligorecurrent mHSPC euoncology.europeanurology.com/article/S2588-…

Prospective study of stereotactic radiation for treatment of brain metastases (1-10) in SCLC (instead of whole brain radiation) Journal of Clinical Oncology. In 100 pts (median number of metastases was 2), only 22% of pts required salvage WBRT, mOS 10.2m. ascopubs.org/doi/10.1200/JC…

❗️ Important work for SCLC 1-10 brain mets -> SRS mOS 10.2 m Only 22% of patients needed salvage WBRT Median 2 brain mets ascopubs.org/doi/10.1200/JC…

Erman Akkus Journal of the @NCCN OncoAlert M. Bolton Jeff Ryckman Nice paper. 70% of pts were treated in 1-3 fractions, which is no longer used due to high toxicity. The MRI SMART trial & MSKCC series showed lower toxicity (including later – SMART median f/u 23 months though from diagnosis) with 5, 15 & 25 fractions with modern tech, so

Dr. Nina Niu Sanford M. Bolton Erman Akkus Journal of the @NCCN OncoAlert Yes I will have to do deep dive for sure but agree less enthusiastic for 1 or 3 Fx & also curious as to what proportion of 5 Fx received 25-33/5 as I would expect concomitant local failure at these doses which may confound RT toxicity. Will read in next few days & report back!

Attention #match2026 & future #RadOnc! Don’t miss our upcoming meet & greet with the Beaumont Radiation Oncology team 8/20/25 and 9/10/25 at 4-5PM EST Sign up today to connect with our residents and explore what makes Beaumont a standout place to train.

ASTRO & ARRO reps met with leadership from the ABR this week to discuss Oral Boards. Check out this statement from the ABR in ASTRONews Summer Edition. We will be working to set up a session with ABR leaders in the Early Career Lounge at #ASTRO25 stay tuned for more info!! 👀

Prophylactic Irradiation of the Contralateral Breast for BRCA Carriers With Early Breast Cancer: A Nonrandomized Clinical Trial | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…

We've got a new case! Check out this 🧠CNS/optic meningioma submitted by Megan Orr from UCSD Rad Onc via the ACRO - American College of Radiation Oncology ACROresident & MIM Software ✈️travel grant! A big thanks to Joshua D. Palmer, MD for reviewing the case with us! Don't forget to utilize our MRI overlays!